Corcept Therapeutics (CORT) Tops Q1 EPS by 2c, provides guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $116.43 +5.57%
EPS Growth %: +406.3%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: +406.3%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.17, $0.02 better than the analyst estimate of $0.15. Revenue for the quarter came in at $157.2 million versus the consensus estimate of $177.94 million.
GUIDANCE:
Corcept Therapeutics sees FY2025 revenue of $900-950 million, versus the consensus of $905.4 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
- Bank of Canada warns new US tariffs may cut Q4 growth below 1%
- FAA extend ground stop to all major NYC airports
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
